doi:10.3969/j.issn.1674-490X.2020.05.002

Abstract

Abstract: Colorectal cancer is one common malignant tumor in the digestive system, and the most common way of blood metastasis is through portal vein system to liver. So early detection and treatment of liver metastasis is the key to improve the prognosis of patients. Radiomics and radiogenomics use non-invasive methods to evaluate the biological properties of tumors by deeply mining the texture features of images, quantifying the heterogeneity of tumors. Radiomics and radiogenomics have been widely used in the detection, treatment and prognosis prediction of CRLM. Based on the background of liver, this paper reviews the current situation and application of radiomics and radiogenomics in CRLM.

Key words: colorectal cancer, liver metastasis, radiomics, gene, treatment, prognosis

CLC Number:

References

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2017[J]. CA: A Cancer J Clin, 2017, 67(1): 7-30. DOI: 10.3322/caac.21387.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3] AKGÜL Ö, ÇETINKAYA E, ERSÖZ ??塁, et al. Role of surgery in colorectal cancer liver metastases[J]. World J Gastroenterol, 2014, 20(20): 6113-6122. DOI: 10.3748/wjg.v20.i20.6113.
[4] 中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠外科学组, 中国抗癌协会大肠癌专业委员会, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2018版)[J]. 中华消化外科杂志, 2018, 17(6): 527-539. DOI: 10.3760/cma.j.issn.1673-9752.2018.06.001.
[5] GILLIES R J, KINAHAN P E, HRICAK H. Radiomics: images are more than pictures, they are data[J]. Radiology, 2016, 278(2): 563-577. DOI: 10.1148/radiol.2015151169.
[6] LAMBIN P, LEIJENAAR R T H, DEIST T M, et al. Radiomics: the bridge between medical imaging and personalized medicine[J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762. DOI: 10.1038/nrclinonc.2017.141.
[7] 吴佩琪, 刘再毅, 何兰, 等. 影像组学与大数据结合的研究现状[J]. 中华放射学杂志, 2017, 51(7): 554-558. DOI: 10.3760/cma.j.issn.1005-1201.2017.07.023.
[8] RAO S X, LAMBREGTS D M, SCHNERR R S, et al. Whole-liver CT texture analysis in colorectal cancer: does the presence of liver metastases affect the texture of the remaining liver? [J]. United European Gastroenterol J, 2014, 2(6): 530-538. DOI: 10.1177/2050640614552463.
[9] GANESHAN B, MILES K A, YOUNG R C, et al. Texture analysis in non-contrast enhanced CT: impact of malignancy on texture in apparently disease-free areas of the liver[J]. Eur J Radiol, 2009, 70(1): 101-110. DOI: 10.1016/j.ejrad.2007.12.005.
[10] 蔡建强. 结直肠癌肝转移诊治进展[J]. 中国临床医生杂志, 2019, 47(8): 886-888. DOI: 10.3969/j.issn.2095-8552.2019.08.002.
[11] DOHAN A, GALLIX B, GUIU B, et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab[J]. Gut, 2020, 69(3): 531-539. DOI: 10.1136/gutjnl-2018-316407.
[12] DERCLE L, LU L, SCHWARTZ L H, et al. Radiomics response signature for identification of metastatic colorectal cancer sensitive to therapies targeting EGFR pathway[J]. J Natl Cancer Inst, 2020,112(9):902-912. DOI: 10.1093/jnci/djaa017.
[13] 张菁, 周裕文, 邱萌, 等. 计算机断层扫描纹理分析在预测联合靶向化疗后的结直肠癌肝转移灶治疗反应的价值研究[J]. 生物医学工程学杂志, 2018, 35(6): 914-920. DOI: 10.7507/1001-5515.201801062.
[14] 胡飞翔, 胡婷丹, 童彤, 等. 基于CT图像纹理分析评价结直肠癌肝转移新辅助治疗后疗效的价值[J]. 肿瘤影像学, 2017, 26(2): 106-113. DOI: 10.3969/j.issn.1008-617X.2017.02.005.
[15] ZHANG H, LI W H, HU F X, et al. MR texture analysis: potential imaging biomarker for predicting the chemotherapeutic response of patients with colorectal liver metastases[J]. Abdom Radiol, 2019, 44(1): 65-71. DOI: 10.1007/s00261-018-1682-1.
[16] 王亚辉, 王建伟. 结直肠癌肝转移患者预后评分体系的变化及发展[J]. 中华普通外科杂志, 2019, 34(11): 1003-1005. DOI: 10.3670/cma.j.issn.1007-631X.2019.11.032.
[17] 梁和月, 阳朝霞, 傅彩霞, 等. 全肝MRI直方图分析检测结直肠癌肝转移复发的价值[J]. 肿瘤影像学, 2017, 26(1): 18-24. DOI: 10.3969/j.issn.1008-617X.2017.01.004.
[18] MILES K A, GANESHAN B, GRIFFITHS M R, et al. Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival[J]. Radiology, 2009, 250(2): 444-452. DOI: 10.1148/radiol.2502071879.
[19] LEE S J, ZEA R, KIM D H, et al. CT texture features of liver parenchyma for predicting development of metastatic disease and overall survival in patients with colorectal cancer[J]. Eur Radiol, 2018, 28(4): 1520-1528. DOI: 10.1007/s00330-017-5111-6.
[20] 谭俊, 袁少勋, 明文龙, 等. 影像基因组学分析方法研究进展[J]. 生物技术进展, 2018, 8(4): 277-283. DOI: 10.19586/j.2095-2341.2018.0045.
[21] ZHANG L, CHEN B, LIU X, et al. Quantitative biomarkers for prediction of epidermal growth factor receptor mutation in non-small cell lung cancer[J]. Transl Oncol, 2018, 11(1): 94-101. DOI: 10.1016/j.tranon.2017.10.012.
[22] JIA T Y, XIONG J F, LI X Y, et al. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling[J]. Eur Radiol, 2019, 29(9): 4742-4750. DOI: 10.1007/s00330-019-06024-y.
[23] KOO H J, KIM M Y, PARK S, et al. Non-small cell lung cancer with resistance to EGFR-TKI therapy: CT characteristics of T790M mutation-positive cancer[J]. Radiology, 2018, 289(1): 227-237. DOI: 10.1148/radiol.2018180070.
[24] WANG H, SCHABATH M B, LIU Y, et al. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations[J]. Eur J Radiol, 2016, 85(11): 1934-1940. DOI: 10.1016/j.ejrad.2016.08.023.
[25] MENDOZA D P, STOWELL J, MUZIKANSKY A, et al. Computed tomography imaging characteristics of non-small-cell lung cancer with anaplastic lymphoma kinase rearrangements: a systematic review and meta-analysis[J]. Clin Lung Cancer, 2019, 20(5): 339-349. DOI: 10.1016/j.cllc.2019.05.006.
[26] YAMAMOTO S, MAKI D D, KORN R L, et al. Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape[J]. AJR Am J Roentgenol, 2012, 199(3): 654-663. DOI: 10.2214/ajr.11.7824.
[27] ZHU Y, LI H, GUO W, et al. Deciphering genomic underpinnings of quantitative MRI-based radiomic phenotypes of invasive breast carcinoma[J]. Sci Rep, 2015, 5(1): 17787. DOI: 10.1038/srep17787.
[28] MAZUROWSKI M A, ZHANG J, GRIMM L J, et al. Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging[J]. Radiology, 2014, 273(2): 365-372. DOI: 10.1148/radiol.14132641.
[29] 张旭婷, 任基伟, 靳宏星, 等. Xp11.2易位/TFE3基因融合相关性肾癌的影像诊断与鉴别诊断[J]. 医学影像学杂志, 2019, 29(6): 997-1001.
[30] WIBMER A G, ROBERTSON N L, HRICAK H, et al. Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer[J]. Abdom Radiol, 2019, 44(8): 2864-2873. DOI: 10.1007/s00261-019-02023-1.
[31] O'KEEFE S J, LI J V, LAHTI L, et al. Fat, fibre and cancer risk in African Americans and rural Africans[J]. Nat Commun, 2015, 28(6): 6342. DOI: 10.1038/ncomms7342.
[32] GIANNAKIS M, MU X J, SHUKLA S A, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 15(4): 857-865. DOI: 10.1016/j.celrep.2016.03.075.
[33] 朱晓丽, 蔡旭, 张玲, 等. 中国结直肠癌患者中KRAS与BRAF基因突变特征及其临床病理相关性[J]. 中华病理学杂志, 2012, 41(9): 584-589. DOI: 10.3760/cma.j.issn.0529-5807.2012.09.003.
[34] ZEINALIAN M, EMAMI M H, NAIMI A, et al. Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome[J]. Iran J Cancer Prev, 2015, 8(1): 11-17.
[35] TANIGUCHI H, YAMAZAKI K, YOSHINO T, et al. Japanese Society of Medical Oncology Clinical Guidelines: RAS(KRAS/NRAS)mutation testing in colorectal cancer patients[J]. Cancer Sci, 2015, 106(3): 324-327. DOI: 10.1111/cas.12595.
[36] 孙毅, 艾尼瓦尔·艾木都拉, 古丽比也·沙比尔, 等. 结直肠癌患者肿瘤组织中 KRAS、BRAF基因突变观察及分析[J]. 山东医药, 2014, 54(43): 8-11. DOI: 10.3969/j.issn.1002-266X.2014.43.003.
[37] 林奇, 周鹏扬, 庄奥博, 等. 同时性结直肠癌原发灶和肝转移灶中KRAS基因突变的一致性分析[J]. 中国临床医学, 2019, 26(4): 549-554. DOI: 10.12025/j.issn.1008-6358.2019.20190830.
[38] 孙屏, 万佳艺, 吴靓骅, 等. 结直肠癌KRAS、NRAS和BRAF基因突变及其与临床病理相关性研究[J]. 中华普通外科杂志, 2016, 31(1): 50-54. DOI: 10.3760/cma.j.issn.1007-631X.2016.01.015.
[39] YE J X. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients[J]. World J Gastroenterol, 2015, 21(5): 1595-1605. DOI: 10.3748/wjg.v21.i5.1595.
[40] 姜晓东, 季楚舒, 李明, 等. 晚期结直肠癌患者癌组织K-ras、BRAF基因突变情况观察[J]. 山东医药, 2019, 59(6): 1-4. DOI: 10.3969/j.issn.1002-266X.2019.06.001.
[41] YANG L, DONG D, FANG M, et al. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?[J]. Eur Radiol, 2018, 28(5): 2058-2067. DOI: 10.1007/s00330-017-5146-8.
[42] 何家鸿, 吴湖炳, 周文兰, 等. 比较PET传统参数与纹理参数在预测结直肠癌KRAS基因突变中的价值[J]. 中华核医学与分子影像杂志, 2018, 38(10): 662-667. DOI: 10.3760/cma.j.issn.2095-2848.2018.10.004.
[43] LUBNER M G, STABO N, LUBNER S J, et al. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes[J]. Abdom Imaging, 2015, 40(7): 2331-2337. DOI: 10.1007/s00261-015-0438-4.
[44] BOLAND C R, GOEL A. Microsatellite instability in colorectal cancer[J]. Gastroenterology, 2010, 138(6): 2073-2087. DOI: 10.1053/j.gastro.2009.12.064.
[45] 王光尧, 陈平, 宗亮. 肿瘤抑癌基因突变与MSI相关性在胃肠道间质瘤中的研究进展[J]. 国际外科学杂志, 2012, 39(7): 468-471. DOI: 10.3760/cma.j.issn.1673-4203.2012.07.012.
[46] BIRKENKAMP-DEMTRODER K, MANSILLA F, SØRENSEN F B, et al. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro[J]. Mol Oncol, 2007, 1(2): 181-195. DOI: 10.1016/j.molonc.2007.05.005.
[47] 韩晶. 结直肠癌微卫星不稳定(MSI)与其发病及预后的关系[J]. 中国肿瘤临床, 2012, 39(1): 56-59. DOI: 10.3969/j.issn.1000-8179.2012.01.015.
[48] 李宇阳, 丁祺, 董丽儒, 等. 错配修复蛋白MLH1 MSH2 MSH6及PMS2 在结直肠癌中的表达及其临床意义[J]. 河北医学, 2019, 25(4): 536-539. DOI: 10.3969/j.issn.1006-6233.2019.04.003.
[49] 陈功. 结直肠癌免疫治疗现状及进展[J]. 精准医学杂志, 2019, 34(1): 1-5. DOI: 10.13362/j.jpmed.201901001.
[50] LUIS A D, LE D T. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 373(20): 1979. DOI: 10.1056/nejmc1510353.
[51] 武敬君, 刘爱连, 赵莹, 等. 能谱CT成像碘(水)图纹理分析预测结直肠癌微卫星不稳定状态[J]. 中国医学影像技术, 2019, 35(11): 1683-1688. DOI: 10.13929/j.1003-3289.201905067.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(5): 29-37.
[2]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(5): 46-52.
[3]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 14-21.
[4]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 22-27.
[5]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 28-37.
[6]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(3): 38-45.
[7]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(2): 1-9.
[8]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(2): 18-24.
[9]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(2): 33-38.
[10]	JIANG Le,WANG Xiaobing,HE Ershu,ZHENG Xiaoye,GONG Zhiting. Effect of RG108 on proliferation and gene expression of HT22 cell line [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(4): 1-7.
[11]	ZHAN Xiaofei, CUI Zhenyu, ZHAO Chunli. Advances on artificial intelligence in the diagnosis and treatment of urinary calculi [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(4): 30-38.
[12]	LI Ruiming, DUAN Kaixuan, CUI Dandan, GUO Yu. Construction of curriculum system of rehabilitation treatment technology specialty based on post standard [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(4): 73-80.
[13]	WANG Jing, HAN Li, ZHANG Zeming. Advances on chronic obstructive pulmonary disease associated pulmonary hypertension [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 21-28.
[14]	WU Chunmei, YIN Xiaoping. Advances on radiomics in adrenal adenoma [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 29-34.
[15]	HAO Jianzhang, ZHANG Hu. Prospect of treatment of retinal vein edema combined with macular edema [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 35-40.